Lawsuit Alert: Investors who lost money with shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) should contact the Shareholders Foundation

An investor, who purchased shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO), filed a lawsuit in the U.S. District Court for the Northern District of California over alleged violations of Federal Securities Laws by Soleno Therapeutics, Inc.

Investors who purchased shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) have certain options and for certain investors are short and strict deadlines running. Deadline: May 5, 2026. NASDAQ: SLNO investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Redwood City, CA based Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Soleno Therapeutics, Inc. commercial product is diazoxide choline extended-release tablets ("DCCR") for the treatment of hyperphagia in individuals afflicted with Prader-Willi syndrome ("PWS").

On August 15, 2025, Scorpion Capital LLC published a critical report regarding Soleno Therapeutics, Inc., DCCR, and Soleno's Phase 3 clinical trial program.

Then, on September 10, 2025, Soleno Therapeutics, Inc. filed with the U.S. Securities and Exchange Commission a current event report on Form 8-K disclosing that a patient had died after taking DCCR, the Soleno shareholder lawsuit alleges.

Finally, on November 4, 2025, Soleno Therapeutics, Inc. reported its financial results for its third fiscal quarter ended September 30, 2025, revealing that the Scorpion Capital Report had caused a "disruption" in DCCR's launch trajectory and concerns within the PWS community, with a lower number of patient start forms and increased discontinuations beginning after the report's publication, the Soleno class action alleges.

The plaintiff claims that between March 26, 2025 and November 4, 2025, the defendants failed to disclose that: (i) the Soleno Phase 3 clinical trial program for DCCR had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (ii) as a result, the administration of DCCR to treat hyperphagia in individuals with PWS posed materially greater safety risks than disclosed by Soleno or its executives; and (iii) consequently, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

Those who purchased shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.